FatDAO addresses the global obesity crisis, aiming to advance research and solutions for weight management and metabolic health. With 2.2 billion overweight or obese adults worldwide, obesity and related diseases like diabetes and cardiovascular conditions severely impact public health and quality of life. Our vision is to become the “on-chain Eli Lilly,” driving breakthroughs in obesity treatment and reshaping the future of metabolic health.
Affected People
Economic Impact
Market Cap
Overweight and obesity pose a severe threat, contributing to numerous health complications and placing a significant strain on the healthcare system.
Traditional weight-loss methods, like diet, exercise, medications, and surgery, can have different levels of success. The most prominent treatment today is semaglutide (Ozempic), a GLP-1 agonist, which has demonstrated significant efficacy. However, ...
Our research explores innovative probiotic strategies for obesity treatment, targeting safer, more cost-effective metabolic interventions. By isolating and validating novel synbiotic combinations, we aim to naturally modulate metabolism and reduce fat accumulation, presenting a promising alternative to traditional pharmacological approaches.
Obesity and metabolic dysfunction accelerate aging processes by disrupting adipose tissue's endocrine function. Our research explores how interventions like targeted probiotics and metabolic modulators can mitigate age-related decline, improve insulin sensitivity, reduce inflammation, and promote healthier longevity.
The gut-brain communication critically influences appetite, mood, and cognition. Metabolic disorders like obesity frequently co-occur with mental health conditions. Fat DAO will fund research exploring how the gut microbiome impacts the gut-brain axis.
FatDAO champions sustainable innovation through our ""Research-Revenue-Research Flywheel.""...
NHI
Clinical Nutrition
NIH